Cargando…

Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer

BACKGROUND: Our objective is to build a model based on Prostate Imaging Reporting and Data System version 2 (PI-RADs v2) and assess its accuracy by internal validation. METHODS: Patients who took prostate biopsy from 2014 to 2015 were retrospectively collected to compose training cohort according to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yu, Zeng, Na, Zhu, Yi Chen, Huang, Yang Xin Rui, Guo, Qiang, Tian, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984817/ https://www.ncbi.nlm.nih.gov/pubmed/29859119 http://dx.doi.org/10.1186/s12957-018-1367-9

Ejemplares similares

Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer
por: Rudolph, Madhuri M., et al.
Publicado: (2020)

Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
por: Li, Tianping, et al.
Publicado: (2022)

Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
por: Viana, Publio Cesar Cavalcanti, et al.
Publicado: (2019)

Impact of PI-RADS v2 on indication of prostate biopsy
por: Rozas, George de Queiroz, et al.
Publicado: (2019)

Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study
por: Cai, Guan-Hui, et al.
Publicado: (2021)

Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
por: Wang, Yunhan, et al.
Publicado: (2023)

Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy
por: Wang, Yu-Hao, et al.
Publicado: (2023)

PI‐RADS 3 score: A retrospective experience of clinically significant prostate cancer detection
por: Camacho, Andrés, et al.
Publicado: (2023)

A PI-RADS-Based New Nomogram for Predicting Clinically Significant Prostate Cancer: A Cohort Study
por: Zhang, Yueyue, et al.
Publicado: (2020)

Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Natale, Caleb, et al.
Publicado: (2021)

A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone
por: Wei, Chaogang, et al.
Publicado: (2021)

Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study
por: Zhou, Yongheng, et al.
Publicado: (2023)

Standardization of Multiparametric Prostate MR Imaging Using PI-RADS
por: Bomers, Joyce G. R., et al.
Publicado: (2014)

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI
por: Chen, Tong, et al.
Publicado: (2022)

Prospective evaluation of PI-RADS v2 and quantitative MRI for clinically significant prostate cancer detection in Indian men – East meets West
por: Kubihal, Vijay, et al.
Publicado: (2022)

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
por: Gomez-Gomez, Enrique, et al.
Publicado: (2021)

Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
por: Li, Mou, et al.
Publicado: (2021)

Value of an online PI-RADS v2.1 score calculator for assessment of prostate MRI
por: Barth, Borna K., et al.
Publicado: (2021)

Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer
por: Dola, Eman F., et al.
Publicado: (2017)

Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
por: Chen, Tong, et al.
Publicado: (2018)

PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone
por: Wen, Jing, et al.
Publicado: (2022)

The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
por: Liu, Jiazhou, et al.
Publicado: (2022)

Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions
por: Jin, Pengfei, et al.
Publicado: (2022)

Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions
por: Brancato, Valentina, et al.
Publicado: (2021)

The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study
por: Chen, Song, et al.
Publicado: (2020)

Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

Detection of clinically significant prostate cancer with PI-RADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions
por: Westphalen, Antonio C., et al.
Publicado: (2019)

Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI‐RADS 3–5 regions of interest
por: Stone, Nelson, et al.
Publicado: (2021)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS
por: Radtke, Jan Philipp, et al.
Publicado: (2019)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Lee, Chung-Un, et al.
Publicado: (2022)

An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines
por: Panebianco, Valeria, et al.
Publicado: (2017)

Machine learning-based analysis of a semi-automated PI-RADS v2.1 scoring for prostate cancer
por: Singh, Dharmesh, et al.
Publicado: (2022)

Prostate MRI based on PI-RADS version 2: how we review and report
por: Steiger, Philipp, et al.
Publicado: (2016)

The role of different PI-RADS versions in prostate multiparametric magnetic resonance tomography assessment
por: Aliukonis, Paulius, et al.
Publicado: (2017)

Standards for MRI reporting—the evolution to PI-RADS v 2.0
por: Spektor, Michael, et al.
Publicado: (2017)

Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with PSA <10 ng/ml and PI‐RADS v2.1 = 3 lesions
por: Hu, Can, et al.
Publicado: (2022)

The Value of Low Prostate Imaging—Reporting and Data System (PI-RADS) Scores in Preventing Unnecessary Prostate Biopsies
por: Kim, Dong-Soo, et al.
Publicado: (2021)

The Impact of Prostate Volume on the Prostate Imaging and Reporting Data System (PI-RADS) in a Real-World Setting
por: Volz, Yannic, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j4dcch3h3p9j59q9irmfhf92f9